logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Orionis Biosciences, Inc.


USPTO Granted Patents = 17


Trademarks = 1

Forward Citations = 6

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Nikolai Kley (17 out of 34 patents)

silverMedal Jan Tavernier (14 out of 73 patents)

bronzeMedal Lennart Zabeau (10 out of 20 patents)

4.  Erik Depla (9 out of 10 patents)

5.  Frank Peelman (2 out of 14 patents)

6.  Anje Cauwels (2 out of 12 patents)

7.  Riccardo Sabatini (2 out of 2 patents)

8.  Bram Van Den Eeckhout (1 out of 1 patent)

9.  Edward Suh (1 out of 1 patent)

10.  Samuel Lievens (1 out of 1 patent)

11.  Sarah Gerlo (1 out of 1 patent)


17 patents:

1. 12758640 - Bifunctional agents for protein recruitment and/or degradation (2026-10-13),
2. 12752000 - IMMUNOSTIMULATORY ADJUVANTS (2026-10-06),
3. 12655186 - CHIMERIC PROTEIN COMPRISING ANTI-XCR1 ANTIBODY AND MODIFIED INTERFERON ALPHA 2 (2026-06-16),
4. 12583941 - Fibroblast activation protein binding agents and use thereof (2026-03-24),
5. 12546776 - Modulation of protein degradation (2026-02-10),
6. 12497436 - CHIMERIC PROTEIN, AND ENCODING NUCLEIC ACID THEREOF, COMPRISING INTERFERON-BETA AND A TARGETING MOIETY COMPRISING A SINGLE-DOMAIN ANTIBODY OR SINGLE-CHAIN ANTIBODY (2025-12-16),
7. 12448447 - CD8 binding agents (2025-10-21),
8. 12410225 - Modulation of dendritic cell lineages (2025-09-09),
9. 12351633 - PD-1 and PD-L1 binding agents (2025-07-08),
10. 12351614 - CLEC9A-based chimeric protein complexes (2025-07-08),
11. 12091463 - Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) (2024-09-17),
12. 12084497 - SIRP1α targeted chimeric proteins and uses thereof (2024-09-10),
13. 11896643 - Fibroblast binding agents and use thereof (2024-02-13),
14. 11566072 - CD8 binding agents (2023-01-31),
15. 11498966 - PD-1 and PD-L1 binding agents (2022-11-15),
Company Overview
Orionis Biosciences, Inc. is a biotechnology company based in Waltham, MA, specializing in the development of innovative therapeutics. The organization focuses on harnessing the power of protein degradation and targeted therapies to address unmet medical needs in various disease areas, including cancer and neurodegenerative disorders. By leveraging advanced research techniques and proprietary technologies, Orionis aims to create transformative solutions that enhance patient outcomes and advance the field of precision medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

17 Patents

#86 in Waltham, MA

#1,150 in Massachusetts

#18,894 in US

#35,918 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Orionis Biosciences, Inc.

Forward Citations = 6

11 inventors:

goldMedal Nikolai Kley (17 out of 34 patents)

silverMedal Jan Tavernier (14 out of 73 patents)

bronzeMedal Lennart Zabeau (10 out of 20 patents)

4.  Erik Depla (9 out of 10 patents)

5.  Frank Peelman (2 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Orionis Biosciences, Inc.. Retrieved from https://idiyas.com/company/orionis-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…